title: [Zrytec drops in the treatment of allergy rhinitis in children].
abstract: OBJECTIVE
  To assess the efficacy and safety of Zyrtec drops which is a patent product of UCB pharma in treatment of allergy rhinitis in children.
  
  
  METHODS
  A total of 47 children of both sexes aged between 2 to 6 years with allergy rhinitis (AR) were included in this study, who were randomly selected to be treated with Zyrtec (Cetirizine 2 HCL) drops 5 mg daily for 3 weeks. Investigators made a global evaluation with symptom scores before treatment and once a week for 3 weeks after treatment.
  
  
  RESULTS
  An improvement was shown in each week after treatment with statistical significance (P < 0.01). Zyrtec drops provided an excellent improvement at the end of the study. Tolerance was good.
  
  
  CONCLUSIONS
  For acting fast, potent, good tolerance and convenience in use, Zyrtec drops is a better treatment in AR in kids.
authors.affiliation: Ninth People's Hospital, Shanghai 200011.
authors.forename: J Y
authors.initials: JY
authors.lastname: Tang
mesh_terms: D017332:Cetirizine / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
chemical_list: D039563:Histamine H1 Antagonists, Non-Sedating; D017332:Cetirizine